User:David Canner/Sandbox 6: Difference between revisions
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
Line 24: | Line 24: | ||
**[[Pore forming toxin, α-hemolsyin|α-hemolsyin]] | **[[Pore forming toxin, α-hemolsyin|α-hemolsyin]] | ||
**[[Amino Acids]] with info about [[Selenocysteine]] and [[Pyrrolysine]] | **[[Amino Acids]] with info about [[Selenocysteine]] and [[Pyrrolysine]] | ||
**[[ACE|Angiotensin Converting Enzyme]] | |||
**[[Annexin]] | **[[Annexin]] | ||
**[[Antizyme Inhibitor]] | **[[Antizyme Inhibitor]] | ||
Line 40: | Line 41: | ||
*D - L | *D - L | ||
**[[David Canner's Favorites]] | |||
**[[DHFR]] | **[[DHFR]] | ||
**[[Dihydrofolate reductase]] | **[[Dihydrofolate reductase]] | ||
Line 78: | Line 80: | ||
**[[User:Eric Martz/Molecular Playground/HIVDrug|HIV Drug]] | **[[User:Eric Martz/Molecular Playground/HIVDrug|HIV Drug]] | ||
**[[Herpes Simplex Virus Thymidine Kinase]] | **[[Herpes Simplex Virus Thymidine Kinase]] | ||
**[[HMGR|HMG-CoA Reductase]] | |||
**[[IgA]] | **[[IgA]] | ||
**[[Influenza hemagglutinin]] | **[[Influenza hemagglutinin]] | ||
Line 106: | Line 109: | ||
**[[OhrR]] | **[[OhrR]] | ||
**[[P53]] | **[[P53]] | ||
**[[PPAR|Peroxisome Proliferator-Activated Receptor]] | |||
**[[PcrA helicase]] | **[[PcrA helicase]] | ||
**[[Personal favorites]] | **[[Personal favorites]] | ||
Line 149: | Line 153: | ||
**[[Treatment of Gaucher disease]] | **[[Treatment of Gaucher disease]] | ||
**[[Tropomyosin]] | **[[Tropomyosin]] | ||
**[[VEGF|Vascular Endothelial Growth Factor]] | |||
**[[VEGFR|Vascular Endothelial Growth Factor Receptor]] | |||
**[[Villin]] | **[[Villin]] | ||
**[[Vinculin]] | **[[Vinculin]] |